318 Results

People

  1. Motzer
    Motzer
  2. Rosenberg
    Rosenberg
  3. Hellmann
    Hellmann
  4. Rudin
    Rudin
  5. Schoenfeld
    Schoenfeld
  6. Iyer
    Iyer
  7. Ladanyi
    Ladanyi
  8. Wolchok
    Wolchok
  9. O'Cearbhaill
    O'Cearbhaill
  10. Rizvi
    Rizvi

Groups

  1. Department of Medicine (217)
  2. Solid Tumor Oncology Division (188)
  3. GSK Faculty (66)
  4. Hematologic Malignancies, Division of (65)
  5. Genitourinary Oncology Service (60)
  6. Department of Pathology and Laboratory Medicine (59)
  7. Sloan Kettering Institute Postdocs (52)
  8. Surgery (49)
  9. Thoracic Oncology (46)
  10. Weinberg Fellows (41)
  1. "programmed death 1 ligand 1"
Formats
  1. Journal Article (231)
  2. Review (46)
  3. Editorial (21)
  4. Correspondence (6)
  5. Guidelines (6)
  6. Research Letter (6)
  7. Miscellaneous (2)
Groups
  1. Department of Medicine (217)
  2. Solid Tumor Oncology Division (188)
  3. GSK Faculty (66)
  4. Hematologic Malignancies, Division of (65)
  5. Genitourinary Oncology Service (60)
  6. Department of Pathology and Laboratory Medicine (59)

More Groups

People
  1. Robert Motzer (20)
  2. Jonathan Rosenberg (16)
  3. Jedd Wolchok (15)
  4. Matthew Hellmann (14)
  5. Adam Schoenfeld (10)
  6. Charles Rudin (10)

More People

Years
  1. 2025 (25)
  2. 2024 (53)
  3. 2023 (44)
  4. 2022 (49)
  5. 2021 (29)
  6. 2020 (43)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (19)
  2. Clinical Cancer Research (17)
  3. Annals of Oncology (15)
  4. Journal of Clinical Oncology (14)
  5. Journal of Thoracic Oncology (8)
  6. New England Journal of Medicine (8)

More Publications

Publishers
  1. Elsevier Inc. (44)
  2. Nature Publishing Group (26)
  3. American Association for Cancer Research (24)
  4. Biomed Central Ltd (21)
  5. Oxford University Press (18)
  6. Elsevier Science, Inc. (17)

More Publishers

Results (318)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Putative biomarkers of clinical benefit with pembrolizumab in advanced urothelial cancer: Results from the KEYNOTE-045 and KEYNOTE-052 landmark trials
    Journal Article

    Bellmunt, J.; de Wit, R.; Fradet, Y.; Climent, M. A.; Petrylak, D. P.; Lee, J. L.; Fong, L.; Necchi, A.; Sternberg, C. N.; O'Donnell, P. H.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • PD-1 or PD-L1 blockade adds little to combination of BRAF and MEK inhibition in the treatment of BRAF V600-mutated melanoma
    Editorial

    Callahan, M. K.; Chapman, P. B.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma
    Journal Article

    Holm, J. S.; Funt, S. A.; Borch, A.; Munk, K. K.; Bjerregaard, A. M.; Reading, J. L.; Maher, C.; Regazzi, A.; Wong, P.; Al-Ahmadie, H.; more...
    Nature Communications (2022)

    Fulltext@MSK | Save
  • Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
    Journal Article

    Shitara, K.; Ajani, J. A.; Moehler, M.; Garrido, M.; Gallardo, C.; Shen, L.; Yamaguchi, K.; Wyrwicz, L.; Skoczylas, T.; Bragagnoli, A. C.; more...
    Nature (2022)

    Fulltext@MSK | Save
  • Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: A multicenter, single-arm, phase II trial
    Journal Article

    Funt, S. A.; Lattanzi, M.; Whiting, K.; Al-Ahmadie, H.; Quinlan, C.; Teo, M. Y.; Lee, C. H.; Aggen, D.; Zimmerman, D.; McHugh, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Incorporation of TILs in daily breast cancer care: How much evidence can we bear?
    Review

    Laenkholm, A. V.; Callagy, G.; Balancin, M.; Bartlett, J. M. S.; Sotiriou, C.; Marchio, C.; Kok, M.; Dos Anjos, C. H.; Salgado, R.
    Virchows Archiv (2022)

    Fulltext@MSK | Save
  • Editorial to the special issue entitled “Imaging in immunooncology”
    Editorial

    Fruhwirth, G. O.; Weigelin, B.; Daldrup-Link, H. E.; Ponomarev, V.
    Molecular Imaging and Biology (2022)

    Fulltext@MSK | Save
  • Breaking up MTDH–SND1 to break down metastasis
    Editorial

    Jiang, Q.; Ganesh, K.
    Nature Cancer (2022)

    Fulltext@MSK | Save
  • Emerging evidence for VEGF and immune checkpoint inhibition in oesophagogastric cancer
    Correspondence

    Ilson, D. H.
    The Lancet Gastroenterology & Hepatology (2022)

    Fulltext@MSK | Save
  • Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: Clinical outcomes and translational biomarker analyses
    Journal Article

    Friedman, C. F.; Spencer, C.; Cabanski, C. R.; Panageas, K. S.; Wells, D. K.; Ribas, A.; Tawbi, H.; Tsai, K.; Postow, M.; Shoushtari, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save